A Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Inhaled RV1729 in Patients With COPD
Phase of Trial: Phase I
Latest Information Update: 06 Jul 2015
Price : $35 *
At a glance
- Drugs RV 1729 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors RespiVert
- 01 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 13 May 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.
- 13 Apr 2015 According to the ClinicalTrials.gov record, planned end date changed from 1 Feb 2015 to 1 Jul 2015.